2020 My Life with Sickle Cell: Patient and Caregiver Survey
In 2020 the Institute for Clinical and Economic Review (ICER) assessed three newer medications, Crizanlizumab, Voxelotor, and L-Glutamine for SCD. In collaboration with ICER, Sick Cells, a U.S. based advocacy organization, developed and fielded an online survey to gather U.S. patient and caregiver work and activity impairment, and out of pocket costs (OOPCs) to include in the review of the medications as contextual information